Charco Neurotech

Executive Summary

Charco Neurotech is a UK-based medical device company revolutionizing Parkinson's disease management with its non-invasive wearable, the CUE1+. The device delivers focused vibrotactile stimulation to alleviate motor symptoms such as slowness, stiffness, and freezing of gait, providing a discreet and patient-centric solution that pairs with a companion app to enhance quality of life. Founded in 2019 and headquartered in London, the company is at the forefront of neurostimulation technology, targeting a large and underserved patient population with an approach that avoids the invasiveness of deep brain stimulation. The company has made significant strides in product development and early clinical validation, with the CUE1+ already available in select markets. Charco Neurotech is now focused on expanding its clinical evidence base and regulatory approvals to penetrate larger markets, including the United States. With a lean team and a clear value proposition, the company is well-positioned to capture market share in the growing wearable neurostimulation space. However, it faces competition from other non-invasive therapies and must demonstrate robust long-term efficacy data to secure broad adoption.

Upcoming Catalysts (preview)

• Q4 2026Completion of pivotal clinical trial for CUE1+60% success
• Q2 2026FDA Breakthrough Device Designation or 510(k) clearance submission50% success
• Q3 2026Strategic commercial partnership in Europe or Asia65% success